CliffBio
biologic

Elfabrio

pegunigalsidase alfa-iwxj

Loss of exclusivityMay 2035projected — 12-year biologic exclusivity estimate
CompanyChiesi Farmaceutici S.p.A. →View the full company profile on CliffBio

Drug detail

Brand nameElfabrio
Active ingredientpegunigalsidase alfa-iwxj
Strength20MG/10ML (2MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2023
Marketing statusRx

More from Chiesi Farmaceutici S.p.A.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Elfabrio patent cliff — loss of exclusivity May 2035 | CliffBio